

Malta, 25 October 2006

Circular No. P11/2006

Dear Healthcare Professional,

Re: Outcome on Review of Cardiovascular Safety of Non-selective NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

Following last year's review of the cardiovascular safety of non-selective NSAIDs¹, the European Medicines Agency (EMA) have further reviewed this issue in the context of their overall benefit-risk profile. The Medicines Authority has participated in these discussions held at the European Medicines Agency (EMA) and is of the opinion that the advice provided in the attached [press release](#) and [Q & A document on non-selective NSAIDs](#) issued by the EMA is opportune and appropriate, and recommends prescribers to follow this advice when prescribing non-selective NSAIDs. The Medicines Authority will issue another statement when more data regarding this group of medicines is made available and assessed.

¹ Detailed in the following Medicines Authority statements: MA Statement P14/2005 (10 June 2005): Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and their recent association with an increased risk of myocardial infarction (heart attack); MA Statement P15/2005 (2 August 2005) re: Non-selective NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) and cardiovascular safety